Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: A 60-month follow-up study

Clinical Drug Investigation

Volumn 31, Issue 6, 2011, Pages 407-415

  Viganò, Alessandra ^a   Bedogni, Giorgio ^b   Manfredini, Valeria ^a   Giacomet, Vania ^a   Cerini, Chiara ^a   Di Nello, Francesca ^a   Penagini, Francesca ^a   Caprio, Cristiana ^a   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Liver Research Centre   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Tenofovir disoproxil fumarate

Indexed keywords

ALPHA 1 MICROGLOBULIN; CREATININE; EFAVIRENZ; LAMIVUDINE; PHOSPHATE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; UNDERWEIGHT; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 79955572798     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11590400-000000000-00000     Document Type: Article

References (40)

1. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009 May; 4 (3): 194-9
2. Atta MG, Deray G, Lucas GM. Antiretroviral nephrotoxicities. Semin Nephrol 2008 Nov; 28 (6): 563-75
3. Rodriguez-Nó voa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010 Jul; 9 (4): 545-59
4. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010 Sep 1; 51 (5): 496-505
5. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004 May; 48 (5): 1469-87 (Pubitemid 38544348)
6. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35 (3): 269-73 (Pubitemid 38280652)
7. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18 (7): 1074-6 (Pubitemid 38591202)
8. Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6 (5): 341-6 (Pubitemid 41335143)
9. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47 (1): 74-8 (Pubitemid 351619372)
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292 (2): 191-201 (Pubitemid 38917996)
11. Shooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002, Jun 14; 16 (9): 1257-63 (Pubitemid 34666660)
12. Moyle GJ, Sabin CA, Cartledge J, et al., RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20 (16): 2043-50 (Pubitemid 44611057)
13. Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51 (3): 290-7
14. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005 Dec; 116 (6): e846-54 (Pubitemid 46056464)
15. Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27 (8): 573-81 (Pubitemid 47124099)
16. Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011; 25 (2): 171-6
17. Cacciari E, Milani S, Balsamo A, et al. Italian crosssectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 2002 Feb; 56 (2): 171-80 (Pubitemid 34145160)
18. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20 (4): 743-6 (Pubitemid 40520651)
19. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003 Jun; 111 (6 Pt 1): 1416-21 (Pubitemid 36682280)
20. Schwartz GJ,Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar; 20 (3): 629-37
21. Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda (MD): NIH, 2005
22. Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994 Apr; 8 (2): 250-1 (Pubitemid 24092267)
23. Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton (FL): Chapman & Hall, 2003
24. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: John Wiley, 2008
25. Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAARTtreated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 2009; 29 (2): 101-9
26. Kruse K, Kracht U, Göpfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982 Mar; 57 (3): 217-23 (Pubitemid 12190341)
27. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42 (2): 283-90 (Pubitemid 43054205)
28. Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 2007 Sep; 8 (6): 411 (Pubitemid 47163275)
29. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006 Jul; 21 (7): 1034-6 (Pubitemid 43885106)
30. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 2009 Jul; 28 (7): 619-25
31. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008 Oct 18; 22 (16): 2155-63
32. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313-20
33. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009 Mar; 28 (3): 204-9
34. D'Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003 Nov; 12 (6): 639-43 (Pubitemid 38186756)
35. Papaleo A, Warszawski J, SalomonR, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J 2007 Oct; 26 (10): 949-51 (Pubitemid 47494169)
36. Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem 1982 Jun; 28 (6): 1330-3 (Pubitemid 12125066)
37. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009 Mar 27; 23 (6): 689-96
38. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested casecontrol study. AIDS 2010 Feb 20; 24 (4): 525-34
39. Guaraldi G, Roverato A, Giovanardi C, et al. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. J Antimicrob Chemother 2009 Feb; 63 (2): 374-9
40. Reid A, Stöhr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIVinfected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008 Apr 15; 46 (8): 1271-81 (Pubitemid 351589914)